Order Article Reprints

Passaro A, Novello S, Giannarelli D, Bria E, Galetta D, Gelibter A, Reale ML, Carnio S, Vita E, Stefani A, et al. Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features. Cancers. 2021; 13(12):2935. https://doi.org/10.3390/cancers13122935

Passaro, Antonio, Silvia Novello, Diana Giannarelli, Emilio Bria, Domenico Galetta, Alain Gelibter, Maria Lucia Reale, Simona Carnio, Emanuele Vita, Alessio Stefani, and et al. 2021. "Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features" Cancers 13, no. 12: 2935. https://doi.org/10.3390/cancers13122935

Passaro, A., Novello, S., Giannarelli, D., Bria, E., Galetta, D., Gelibter, A., Reale, M. L., Carnio, S., Vita, E., Stefani, A., Pizzutilo, P., Stati, V., Attili, I., & de Marinis, F. (2021). Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features. Cancers, 13(12), 2935. https://doi.org/10.3390/cancers13122935